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The inhibitory reversible oxidation of protein tyrosine phospha-
tases (PTPs) is an important regulatory mechanism in growth fac-
tor signaling. Studies on PTP oxidation have focused on pathways
that increase or decrease reactive oxygen species levels and
thereby affect PTP oxidation. The processes involved in reactiva-
tion of oxidized PTPs remain largely unknown. Here the role of the
thioredoxin (Trx) system in reactivation of oxidized PTPs was
analyzed using a combination of in vitro and cell-based assays.
Cells lacking the major Trx reductase TrxR1 (Txnrd1−/−) displayed
increased oxidation of PTP1B, whereas SHP2 oxidation was un-
changed. Furthermore, in vivo-oxidized PTP1B was reduced by
exogenously added Trx system components, whereas SHP2 oxida-
tion remained unchanged. Trx1 reduced oxidized PTP1B in vitro
but failed to reactivate oxidized SHP2. Interestingly, the alterna-
tive TrxR1 substrate TRP14 also reactivated oxidized PTP1B, but
not SHP2. Txnrd1-depleted cells displayed increased phosphoryla-
tion of PDGF-β receptor, and an enhanced mitogenic response,
after PDGF-BB stimulation. The TrxR inhibitor auranoﬁn also in-
creased PDGF-β receptor phosphorylation. This effect was not ob-
served in cells speciﬁcally lacking PTP1B. Together these results
demonstrate that the Trx system, including both Trx1 and TRP14,
impacts differentially on the oxidation of individual PTPs, with a
preference of PTP1B over SHP2 activation. The studies demonstrate
a previously unrecognized pathway for selective redox-regulated
control of receptor tyrosine kinase signaling.
redox regulation | cell signaling
Classical protein tyrosine phosphatases (PTPs) display a con-served active site HC(X5)R signature that renders them
speciﬁc for phosphotyrosine (1–3). PTPs act as modiﬁers of
growth factor-induced signaling and have important roles during
development and in pathological conditions, such as cancer, di-
abetes, and inﬂammation (1–3).
The active sites of PTPs typically display a lowered pKa of the
catalytic cysteine residue (4–7), which therefore is predominantly
present as a reactive thiolate (-S−) that promotes the dephos-
phorylating reaction. However, the reactive cysteine thiolate in
the active site also makes PTPs highly susceptible to inhibitory
oxidation. Multiple molecular variants of oxidized PTPs have
been described, including a sulfenic acid derivative (-SOH) or
a sulfenylamide form involving the main chain nitrogen of the
serine residue juxtaposed to the active site cysteine (8, 9). Other
oxidized versions of PTPs include glutathionylated, nitrosylated,
and sulfhydrated forms, or variants with internal disulﬁdes or
irreversibly oxidized sulﬁnic (-SO2) or sulfonic (-SO3) derivatives
(8–13).
Growth factors like EGF, PDGF, and insulin, that act through
tyrosine kinase receptors, induce reactive oxygen species (ROS)
and oxidation of a selected number of PTPs (14–17). PTP oxida-
tion has also been demonstrated after activation of other classes
of cell surface receptors, such as integrins, G protein coupled
receptors (GPCRs), and B- and T-cell receptors (18–22). The
mechanisms involved still remain incompletely characterized
but include cell surface receptor-induced activation of NADPH
oxidases (NOXs) and spatially restricted inhibitory tyrosine
phosphorylation of peroxiredoxins (Prxs) (20, 23–26). Recent
studies have also implied ROS derived from the mitochondrial
respiratory chain as regulators of PTP oxidation (18, 27). As for
the molecular identity of the relevant oxidants, most studies
have focused on hydrogen peroxide, but peroxidized lipids and
oxidized glutathione have also been identiﬁed as mediators of
PTP oxidation (28, 29).
Studies in which ROS producers and scavengers have been
overexpressed or deleted have demonstrated that PTP oxidation
represents a general mechanism for cross-talk between redox-
and growth factor signaling (reviewed in ref. 30). Some key
ﬁndings in this context involve the modulation of growth factor
signaling, occurring together with altered PTP oxidation, after
manipulation of the expression levels or activities of members of
the Prx-, glutathione peroxidase (GPx)-, NOX, and superoxide
dismutase protein families (21, 23, 31–33).
Physiologically relevant PTP oxidation is a reversible process.
This suggests that reactivation of oxidized PTPs represents an
additional potential control mechanism impacting on PTP oxida-
tion and growth factor signaling. However, this aspect of regu-
lation of PTP activity remains largely unexplored. The major
reducing systems of cells, which should be plausible candidates
for reactivation of reversibly oxidized PTPs, are the thioredoxin
(Trx) and glutathione (GSH) systems. Both areNADPH-dependent,
oxidoreductase-dependent systems with a large range of cellular
functions, often functionally overlapping with each other.
In the Trx system, NADPH is used by isoenzymes of selenium-
dependent thioredoxin reductase (TrxR) that maintain the active
site motif of Trx isoenzymes in the reduced dithiol state, which in
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turn reduce protein targets to maintain, for example, antioxidant
defense, DNA proliferation, transcription factor regulation, and
apoptosis regulation (34, 35). The most prominent and ubiqui-
tously expressed components of the Trx system are the cytosolic
TrxR1 (encoded by the Txnrd1 gene) and its main substrate Trx1
(34, 35). Another less characterized substrate of TrxR1 is TRP14
(36), discovered as a TrxR1-dependent oxidoreductase affecting
TNF-α–induced NF-κB activation, which displays a more re-
stricted substrate speciﬁcity than Trx1 (37, 38).
In the GSH system, NADPH is used by glutathione reductase
that reduces glutathione disulﬁde to GSH, which is used by iso-
enzymes of the GST and glutaredoxin (Grx) family of proteins.
These protect cells from xenobiotics (39) or maintain protein
targets in a reduced state, essentially analogously to the Trx system
(40), although there are also clear differences in some func-
tions and targets between Trx and Grx systems (41).
A few earlier studies have described a capacity of selected
reducing proteins to reactivate oxidized PTPs (12, 14, 42). These
studies have mostly been done in cell-free systems and have not
explored the potential impact of cellular reducing pathways on
growth factor signaling.
In this study the potential role of the Trx system in regulation
of PTP oxidation was analyzed, with a focus on its effects on the
oxidation status of two selected PTPs; PTP1B and SHP2.
A combination of cell- and in vitro-based experiments dem-
onstrated that TrxR1, via either of its two substrates Trx1 and
TRP14, can regulate the oxidation of PTP1B, but not SHP2, in
a manner that affects growth factor and receptor tyrosine kinase
signaling.
Results
Oxidation of PTP1B, but Not SHP2, Is Increased in Txnrd1−/− Cells. To
analyze the importance of the cytosolic Trx system for regulation
of PTP oxidation, the oxidation states of PTP1B and SHP2 were
monitored in mouse embryonic ﬁbroblasts (MEFs) with WT or
Txnrd1 knockout (Txnrd1−/−) genotypes (43).
Analyses of immunoprecipitated PTP1B showed increased
oxidation of PTP1B in Txnrd1−/− cells compared with WT cells
(Fig. 1A). Corresponding analyses of SHP2 showed the reverse
effect (Fig. 1B). Independent evidence for differential effects on
the oxidation status of PTP1B and SHP2 by Txnrd1 deletion was
obtained in experiments on the same cells using a cysteinyl-
labeling assay (44). In this assay the difference in PTP1B oxidation
between the cells became even more evident (Fig. 1C), whereas
SHP2 oxidation showed no signiﬁcant difference (Fig. 1D).
No differences in overall cellular ROS levels were detected
when comparing WT and Txnrd1−/− cells (Fig. 1E), in agreement
with previous ﬁndings showing compensatory up-regulation of
the GSH system in TrxR1 null cells (45).
Taken together these experiments demonstrated that deletion
of Txnrd1 in MEF cells led to an increased oxidation state of
PTP1B, which occurred in the absence of major effects on SHP2
oxidation and which was not related to overall cellular levels of
ROS. The experiments thus suggest that different PTPs display
a differential dependency on TrxR1 for their oxidation state not
related to the generalized cellular oxidation state.
Exogenous Trx System Components Reactivate in Vivo-Oxidized PTP1B
but Not SHP2. The effects of addition of components of the Trx
system to cell lysates were subsequently analyzed in relation to
PTP oxidation status.
To induce oxidation of PTPs, cultured NIH 3T3 cells were
initially treated with 400 μM H2O2 for 5 min. The activities of
PTP1B and SHP2 were subsequently analyzed in control cell
lysates, as well as in lysates incubated with the major components
of the cytosolic Trx system (Trx1, TrxR1, and NADPH) and in
lysates treated with the strong artiﬁcial reducing agent DTT. The
activities with DTT were assumed to represent those of fully
reduced PTP species. As shown in Fig. 2A, the Trx system com-
ponents added to cell lysates signiﬁcantly reactivated PTP1B,
whereas the activity and thus oxidation state of SHP2 remained
unaffected.
These experiments thus provided independent evidence for
a role of the Trx system in controlling the oxidation state and
activity of PTP1B.
The Trx System Reduces Oxidized Recombinant PTP1B in Vitro but Not
SHP2.To further characterize the effects of Trx1 on PTP oxidation,
a set of experiments were performed to analyze the ability of Trx1
to reactivate in vitro-oxidized recombinant PTP1B and SHP2.
Analyses of oxidized recombinant PTP1B demonstrated the
induction of a linear time-dependent peptide dephosphoryla-
tion activity upon incubation with DTT. A combination of Trx1,
TrxR1, and NADPH (Trx1/TrxR1/NADPH) showed a reactivat-
ing capacity for PTP1B, which in this assay was similar to that of
5 mM DTT (Fig. 3 A and B). Additional experiments demon-
strated a clear dose dependency in the ability of Trx1 to activate
oxidized PTP1B (Fig. 3C). Further analyses showed that TrxR1
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Fig. 1. Deletion of Txnrd1 leads to increased oxidation of PTP1B but not
SHP2. Immunoprecipitated PTP1B (A) and SHP2 (B) from immortalized WT
and Txnrd1−/− MEFs were assayed for activity under reducing (including DTT
treatment) and nonreducing conditions. Bars represent the fraction of re-
duced PTPs (n = 4, ±SEM). (C and D) The basal oxidation status of PTP1B and
SHP2 was monitored in WT and Txnrd1−/− MEFs using a cysteinyl-labeling
assay. Bars show oxidation status after normalization to expression levels
(n = 3, ±SEM). (E ) Basal ROS levels in WT and Txnrd1−/− cells were deter-
mined by measuring CellROX ﬂuorescence (n = 3).
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alone together with NADPH could induce a modest activation of
PTP1B but that the full combination of NADPH, TrxR1, and
Trx1 provided the most potent reactivation capacity (Fig. 3D). In
contrast, the complete Trx system could only to a minor extent
reactivate oxidized recombinant SHP2 (Fig. 3E). Finally, sub-
strate-trapping experiments with active site mutants of Trx1
clearly revealed the formation of a DTT-sensitive intermo-
lecular disulﬁde-linked complex between oxidized PTP1B and
a C35S variant of Trx1, whereas no complex could be formed
together with either WT Trx1, the C32S variant, or the active
site double mutant of Trx1 (Fig. 3F). Because Cys32 of Trx1
provides the nucleophilic attack on substrates with Cys35 being
the resolving residue (46), this ﬁnding strongly suggests that
PTP1B is reduced by Trx1 through formation of a transient
intermolecular disulﬁde intermediate, with Cys32 acting as
the attacking nucleophile.
Together these experiments provide independent evidence for a
selective effect of the Trx system on reactivation of oxidized PTPs.
Deletion of Txnrd1 in MEFs Leads to an Increase in PDGF-β Receptor
Phosphorylation. Activation of PDGF-β receptor (PDGFβR) is
associated with phosphorylation of speciﬁc tyrosine residues, re-
quired for downstream signaling. PTPs, including PTP1B, reg-
ulate this receptor phosphorylation in a site-speciﬁc manner
(47–49). Because PTP1B showed a decreased activity and higher
oxidation state in Txnrd1−/− cells, experiments were performed
to analyze whether PDGFβR phosphorylation was affected by
Txnrd1 deletion.
Upon activation of PDGFβR with PDGF-BB an increased re-
ceptor tyrosine phosphorylation was observed in Txnrd1−/− cells,
compared with WT cells (Fig. 4A). Furthermore, the PDGFβR
site pY579-581, known to be regulated by PTP1B (47–49), also
showed an increase in phosphorylation levels in Txnrd1−/− cells
upon ligand stimulation (Fig. 4B). In contrast, no changes were
seen at the SHP2-regulated PDGFβR site pY771 (Fig. 4C).
The increased PDGFβR tyrosine phosphorylation in Txnrd1−/−
cells was paralleled by an enhanced growth-stimulatory response
to PDGF-BB, compared with WT ﬁbroblasts (Fig. 4D).
These experiments thus identiﬁed a cross-talk of the cellular
TrxR1-dependent Trx system with growth factor and receptor
tyrosine kinase signaling.
PTP1B Is Involved in Trx1-Dependent Modulation of PDGFβR Phos-
phorylation. Next, a set of experiments was performed to inves-
tigate whether the increased phosphorylation of the pY579-581
residues of PDGFβR in Txnrd1−/− cells could be related to in-
creased oxidation and thus decreased activity of PTP1B. For this
purpose the effects on PDGFβR phosphorylation of the TrxR1
inhibitor auranoﬁn were analyzed in cells deﬁcient in PTP1B
(Ptpn1−/−) as well as in PTP1B-reconstituted Ptpn1−/− cells (hPtpn1).
In agreement with previous studies (47), the absence of PTP1B
was associated with an increased total tyrosine phosphorylation of
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Fig. 2. Exogenous Trx system components reactivate in vivo oxidized PTP1B
but not SHP2. NIH 3T3 cells were treated with H2O2 to oxidize endogenous
PTPs. Immunoprecipitated PTP1B (A) (n = 3, ± SEM) and SHP2 (B) (n = 4, ±
SEM) were left untreated (Ctrl) or treated with thioredoxin system compo-
nents (Trx) or DTT and assayed for PTP activity. Bars represent the fraction of
reduced PTPs.
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Fig. 3. The Trx system reduces oxidized recombinant PTP1B but not SHP2. Recombinant oxidized PTP1B (A and B) (n = 3–8, ±SEM) and SHP2 (E ) (n =
4–6, ±SEM) were left untreated (Ctrl) or treated with the Trx system (Trx) or DTT. Oxidized recombinant PTP1B was also treated with increasing
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(n = 3, ±SEM). PTP activity was measured over time and turnover rates calculated using the slope from the generated graphs. Substrate trapping of
PTP1B was analyzed by immunoblotting with antibodies for Trx1 using samples of different variants of Trx mixed with oxidized PTP1B and analyzed
on SDS/PAGE in the presence or absence of DTT, as indicated in F.
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PDGFβR and in the phosphorylation of the pY579-581 sites
(Fig. 4E). Importantly, treatment of cells with the TrxR1 inhibitor
auranoﬁn increased phosphorylation levels at the pY579-581 in
the PTP1B-expressing cells, but this effect was clearly diminished
in Ptpn1−/− cells (Fig. 4E).
These experiments thus strongly imply the TrxR1-dependent
regulation of PTP1B as one of the critical intermediates in the
cross-talk between the Trx system and PDGFβR signaling.
TRP14 Is Also Capable of Reactivating Oxidized PTP1B. Although the
experiments described above demonstrated that Trx1 can me-
diate the dependence of PTP1B upon TrxR1 for its reactivation,
it cannot be ruled out that other substrates of TrxR1 can also
contribute to the observed effects. Experiments were thus per-
formed to analyze whether the recently characterized alternative
TrxR1 substrate TRP14 (38) could also reduce oxidized PTP1B.
Experiments designed as in Fig. 3 were thus performed with
TRP14 in place of Trx1. This revealed that TRP14, together with
TrxR1 and NADPH, indeed demonstrated a dose-dependent
effect on PTP1B activity, whereas oxidized SHP2 could not be
reactivated (Fig. 5).
This experiment showed that TRP14 is another redox active
protein that, in addition to Trx1, can mediate the TrxR1-dependent
activation of oxidized PTP1B.
Discussion
This study identiﬁes previously unrecognized selective effects of
the Trx system on the oxidation state of PTP1B, associated with
modulation of biochemical and cellular PDGF responsiveness.
This pathway for control of PDGF signaling may also be relevant
for other growth factors acting through tyrosine kinase receptors.
Interestingly, the Trx system did not seem to be important for the
control of SHP2 oxidation, suggesting an earlier neglected level
of speciﬁcity in the processes of reactivation of oxidized PTPs.
Finally, TRP14 was identiﬁed as an additional TrxR1-dependent
regulator of the oxidation of PTP1B but not SHP2.
Previous work addressing reactivation of oxidized PTPs, using
recombinant PTPs in vitro, showed an ability of Trx1 to reactivate
oxidized PTP1B with a potency similar to that of DTT (12, 14),
which is in line with this work. In another study, which charac-
terized the role of oxidized “backdoor cysteines” of SHP2,
reactivating ability was demonstrated by DTT and GSH, whereas
no effect was seen by Trx system components (42). Interestingly,
the latter study demonstrated that the catalytic domain of SHP2
was sensitive to Trx system component reduction (42), indicating
that determinants controlling the differential effects of the Trx
system and GSH reside in structure(s) outside the catalytic domain.
The fact that TrxR1-dependent reductive pathways efﬁciently
activate PTP1B but not as efﬁciently SHP2 (Fig. 1–3) has inter-
esting implications in view of the role(s) of the Trx system in
signaling pathways and metabolic homeostasis. Whole-body
knockout mouse models for either TrxR1 or Trx1 are embryon-
ically lethal (50, 51). It is interesting to note that liver-speciﬁc
knockouts for both Ptpn1 and Txnrd1 have been made (52–54). It
will be an interesting topic for future studies to investigate
similarities and differences of these mice related to receptor-
dependent signaling pathways.
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The phenotype of a TRP14 knockout in animal models is not
known. The ﬁnding that TRP14 is another TrxR1-dependent
activator of oxidized PTP1B is nonetheless most interesting (Fig.
5). TRP14 was originally described as a dynein light chain LC8-
interacting protein that inhibits NF-κB signaling upon TNF-α
stimulation of HeLa cells (37). Although TRP14 shares many
structural features with Trx1, this redoxin cannot reduce classic
Trx1 protein disulﬁde substrates, such as ribonucleotide reductase,
peroxiredoxins, or methionine sulfoxide reductases (36, 55). The
efﬁcient reactivation of PTP1B by TRP14 identiﬁes TRP14 as
a TrxR1 substrate with speciﬁc functions in modulation of cel-
lular signaling pathways. The relative importance of TRP14 vs.
Trx1 in regulation of PTP1B oxidation remains to be determined
in future studies.
The ﬁnding of a PTP1B-dependent, auranoﬁn-mediated effect
on PDGFβR phosphorylation was also notable. On the basis of
the inactivation of PTP1B in Txnrd1−/− cells, the stimulatory
effects of auranoﬁn on PDGFβR phosphorylation are inter-
preted to be a consequence of effects of auranoﬁn on TrxR1
(56). It should be noted that auranoﬁn has also been shown to
act as a direct PTP inhibitor (57). However, direct inhibition of
PTP1B by auranoﬁn was inefﬁcient and showed an IC50 of >400
μM (57), whereas auranoﬁn inhibits TrxR1 at stoichiometric
submicromolar concentrations (56). Thus, our ﬁndings collec-
tively lead to the conclusion that auranoﬁn in the present study
affects PDGFβR phosphorylation through inhibitory effects on
TrxR1, rather than by direct effects on PTP1B. It should be
noted, however, that other PTPs such as PTPN12 seem to be
more sensitive to direct inhibition by auranoﬁn (57).
The present study demonstrates striking differences between
PTP1B and SHP2 with regard to their susceptibility to reac-
tivation by Trx1 and TRP14. The experiments do not identify the
molecular basis for this differential sensitivity, but a number of
possibilities can be envisioned. First, it is possible that yet-to-be-
deﬁned sequence-speciﬁc interactions occur between Trx1 and
TRP14 within the active-site region of PTP1B that facilitate
Trx1- and TRP14-mediated reactivation of PTP1B. Second, the
type of oxidative modiﬁcation(s) of the two PTPs may differ. The
oxidized version described for PTP1B are sulfenic, sulﬁnic, and
sulfonic acid derivatives, as well as forms with an intramolecular
sulfenylamide, and variants containing S-Nitrosylated and glu-
tathionylated cysteines. As for SHP2, sulfenic acid forms and
species with inter- and intramolecular disulphide bonds have
been observed (9, 11, 13, 42, 58–61). Future studies should ad-
dress to what extent these different types of oxidized variants
display biologically relevant differential sensitivity to the major
cellular reducing systems. It is also noted that SHP2 sensitivity to
various reductants could vary depending on it being in a “closed”
or “open” conformation. However, on the basis of the absence of
Trx1-dependent alterations in the phosphorylation of the PDGF
receptor SHP2 target site in vivo (Fig. 4C), this study suggests
that the “open” conformation is not regulated by Trx1.
A number of additional topics for continued analyses are sug-
gested by the ﬁndings of this study. It remains to obtain a com-
plete picture of how conditional Trx1, or TRP14, deletion affects
the oxidation state of the whole “PTPome” in different cell types,
and downstream effects on signaling events. One interesting
ﬁnding to further explore is the fact that TrxR1 knockout mice
display early embryonic lethality (50, 51), although the enzyme is
dispensable in several conditional knockouts (52–54). Future
studies should investigate whether this is related to aberrant sig-
naling pathways related to inactivation of speciﬁc PTPs. Recent
mass spectrometry-based methods for analyses of global PTP ox-
idation in different tissues and cells should be highly useful in this
context (62). Our present ﬁndings should also stimulate further
analyses of whether Trx system components are subject to direct
control by tyrosine kinase signaling, as has been described for PTP
oxidation-inducing NOX enzymes (20, 23, 24).
On the basis of the identiﬁcation of TrxR1-mediated control
of growth factor signaling, it will be highly interesting to inves-
tigate whether alterations in TrxR1 levels or activity, as observed
for example in an animal model of liver cancer (54) and ar-
rhythmia (63), are associated with etiologically relevant alter-
ations in growth factor and receptor tyrosine kinase signaling.
Materials and Methods
Cell Culture and Reagents. The MEFs used in this study have been described
before in the context of TrxR1 (43) and PTP1B (48) and were cultured in
DMEM with 10% (vol/vol) FBS, 2 mM L-glutamine, and 20 nM sodium sele-
nite with penicillin and streptomycin. Details about antibodies and other
reagents are given in SI Materials and Methods.
Assays of PTP Oxidation. The cysteinyl-labeling assay of PTP oxidation was
performed as described in ref. 64. The activity-based assay followed proce-
dures as described in ref. 27.
Crystal Violet Assay to Analyze Cell Growth. WT and Txnrd1−/− MEFs were
seeded at 2 × 103 per well of a 96-well plate. The next day medium was re-
placed by low serum-containing medium (1% FBS) with or without 50 ng/mL
PDGF-BB. After 3 d culture cells were ﬁxed using 2% (wt/vol) formaldehyde.
Then cells were stained with 0.04% crystal violet/1% EtOH, and the plate
was dried thoroughly. The relative number of cells per well was determined
by resolving crystal violet in 1% SDS and measuring the absorbance at
590 nm.
ROS Measurement. Cells were grown overnight to 70% conﬂuency and then
starved for 24 h in medium containing 1% FCS. Cells were incubated for
30 min with 5 μM CellROX (Life Technologies), washed three times with
PBS, trypsinized and collected, and kept on ice before analysis on a Becton
Dickinson FACSCalibur, and data were analyzed using Cyﬂogic software.
Analyses of PDGFβR Phosphorylation. PDGFβR phosphorylation was analyzed
from starved cells after 5 min of 50 ng/mL PDGF-BB stimulation. Where in-
dicated, cells received a 1-h treatment with 1 μM auranoﬁn before stimu-
lation. A detailed description is provided in SI Materials and Methods.
Treatment of Cell Lysates with Trx System Components. NIH 3T3 cells were
treated with 400 μM H2O2 for 5 min. After lysis cleared cell lysates were
treated with a combination of Trx system components (Trx1 10 μM, TrxR1
0.5 μM, and NADPH 1 mM) or 50 mM DTT for 30 min. Activity assays of PTP1B
and SHP2 was performed as described above. A detailed description is pro-
vided in SI Materials and Methods.
In Vitro Treatments of Recombinant PTP1B and SHP2with Trx System Components.
Recombinant PTP1B and SHP2 were incubated with Trx system components
(Trx1 or TRP14 10 μM, TrxR1 0.5 μM, and NADPH 1 mM) in 50 mM Tris and
2 mM EDTA for 30 min before analysis with PTP activity assay. A detailed
description is provided in SI Materials and Methods.
Substrate Trapping in Vitro of PTP1B by Trx1 Mutant Variants. Recombinant
variants of N-terminally his-tagged human Trx1 of 14.6 kDa (WT, C32S, C35S,
and the active site double mutant C32SC35S) were prereduced with 20-fold
molar excess of DTT, desalted, and subsequently incubated with equal
amounts of oxidized PTP1B (500 nM each) for 20 min at room temperature
and subsequently analyzed by SDS/PAGE, with or without DTT, followed by
Western blot using antibodies against Trx. A detailed description is provided
in SI Materials and Methods.
Statistical Analysis. All statistical analysis was performed using unpaired two-
tailed Student’s t test.
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